Location: Online, Virtual
Date: June 9 to June 17
The QUAZAR AML-001 Maintenance Trial
Prof. Eytan Stein talked about maintenance therapy for acute myeloid leukemia.
Idecabtagene vicleucel, a BCMA-directed CAR T cell therapy, in patients with relapsed and refractory multiple myeloma
Prof. Oriol speaks about the updated results of KarMMa trial.
Novelties in the treatment of Multiple Myeloma
Prof. Ocio give us a brief overview about the main messages of the studies presented on EHA 2021 regarding multiple myeloma.
Treatment of hematological malignancies in 2021
Prof. Corradini speaks about the advance of CAR T-cell therapies and T-cell engaging antibodies.
Novelties in the treatment of chronic myeloid leukemia
Prof. Saglio speaks about the latest news came out from the EHA meeting in the field of CML treatment.
Novelties in the treatment of follicular lymphoma
Prof. Hübel speaks about the latest news came out from the EHA meeting in the field of follicular lymphoma treatment.
Harnessing the immune system in multiple myeloma: CAR T-cell therapy and bispecific antibodies
Prof. Leleu speaks about the clinical and practical aspects of the topic.
Results from the JAKARTA and JAKARTA2 trials
Overall and progression-free survival in patients treated with fedratinib as first-line myelofibrosis therapy and after prior ruxolitinib.
Novelties on the treatment of Multiple Myeloma
Prof. Mohty shares with us his personal thought in the recent advances in multiple myeloma.